The DOI matches its Crossref record.
Cardiac and Glycemic Benefits of Troglitazone Treatment in NIDDM
Abstract
Troglitazone is a thiazolidinedione under development for the treatment of NIDDM and potentially other insulin-resistant disease states. Treatment with troglitazone is associated with an improvement in hyperglycemia, hyperinsulinemia, and insulin-mediated glucose disposal. No significant side effects have been observed in humans. Because of reported cardiac changes in animals treated with drugs of this class, this multicenter 48-week study was conducted to evaluate whether NIDDM patients treated with troglitazone develop any cardiac mass increase or functional impairment. A total of 154 NIDDM patients were randomized to receive troglitazone 800 mg q.d. or glyburide titrated to achieve glycemic control (≤20 mg b.i.d. or q.d.). Twodimensional echocardiography and pulsed Doppler were used to measure left ventricular mass index (LVMI), cardiac index (CI), and stroke volume index (SVI). All echocardiograms were performed at each center (baseline, 12, 24, 36, and 48 weeks), recorded on videotape, and forwarded to a blinded central echocardiographic interpreter for analysis. The results showed that LVMI of patients treated with troglitazone was not statistically or clinically different from baseline after 24 or 48 weeks. Statistically significant increases in SVI and CI and a statistically significant decrease in diastolic pressure and estimated peripheral resistance were observed in troglitazone-treated patients. These results were not sex-specific. Glycemic benefits of troglitazone treatment were observed as evidenced by long-term improvement of HbA1c and C-peptide levels. Furthermore, triglycerides were significantly lower, and HDL was significantly higher at weeks 24 and 48. In conclusion, NIDDM patients treated with troglitazone do not show any cardiac mass increase or cardiac function impairment. Conversely, patients on troglitazone benefited from enhanced cardiac output and stroke volume, possibly as a result of decreased peripheral resistance. Treatment with troglitazone appears to have a favorable impact on known cardiovascular risk factors and could potentially lower cardiovascular morbidity in NIDDM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Pharmacologic Therapy for Type 2 Diabetes Mellitus
DeFronzo, R. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-4-199908170-00008 · Cited by 1,173
“Other Effects Troglitazone consistently reduces plasma triglyceride levels by 10% to 20% and increases HDL cholesterol levels by 5% to 10% (128, 129, 136, 138).”
BackgroundResultThomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Boden, G. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.06.007 · Cited by 853
Terminal Differentiation of Human Breast Cancer through PPARγ
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 851
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 829
(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
PPARγ, the ultimate thrifty gene
Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612
Natural product agonists of peroxisome proliferator-activated receptor gamma (PPARγ): a review
Wang, L., Waltenberger, B., Pferschy-Wenzig, E.-M., Blunder, M., Liu, X., Malainer, C., Blazevic, T., Schwaiger, S., Rollinger, J. M., Heiss, E. H., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.018 · Cited by 594
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
The role of PPAR-γ in macrophage differentiation and cholesterol uptake
Moore, K. J., Rosen, E. D., Fitzgerald, M. L., Randow, F., Andersson, L. P., Altshuler, D., Milstone, D. S., Mortensen, R. M., Spiegelman, B. M., & Freeman, M. W. (2001) · Nature Medicine · doi:10.1038/83328 · Cited by 513
Meigs, J. B., Wilson, P. W. F., Nathan, D. M., D’Agostino, R. B., Williams, K., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.8.2160 · Cited by 464
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Thiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
Nonhypoglycemic Effects of Thiazolidinediones
Parulkar, A. A., Pendergrass, M. L., Granda-Ayala, R., Lee, T. R., & Fonseca, V. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-1-200101020-00014 · Cited by 412
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 377
Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y.-H., Ricote, M., Glass, C. K., Brewer, H. B., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2607-2619.2002 · Cited by 368
Chao, L., Marcus-Samuels, B., Mason, M. M., Moitra, J., Vinson, C., Arioglu, E., Gavrilova, O., & Reitman, M. L. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11245 · Cited by 356
Troglitazone action is independent of adipose tissue.
Burant, C. F., Sreenan, S., Hirano, K., Tai, T. A., Lohmiller, J., Lukens, J., Davidson, N. O., Ross, S., & Graves, R. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119839 · Cited by 334
Safety issues and prospects for future generations of PPAR modulators
RUBENSTRUNK, A., HANF, R., HUM, D., FRUCHART, J., & STAELS, B. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2007.02.003 · Cited by 309
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303
Ricote, M., Huang, J. T., Welch, J. S., & Glass, C. K. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.5.733 · Cited by 304
Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease
Guan, Y., & Breyer, M. D. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00766.x · Cited by 295
The metabolic syndrome in children and adolescents
Cruz, M. L., & Goran, M. I. (2004) · Current Diabetes Reports · doi:10.1007/s11892-004-0012-x · Cited by 294
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286
Lessons from the glitazones: a story of drug development
Gale, E. A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04960-6 · Cited by 287
Thiazolidinediones in Type 2 Diabetes Mellitus: Current Clinical Evidence
Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 277
St. John Sutton, M., Rendell, M., Dandona, P., Dole, J. F., Murphy, K., Patwardhan, R., Patel, J., Freed, M., & For the Rosiglitazone Clinical Trials Study Group (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2058 · Cited by 254
Tack, C. J. J., Ong, M. K. E., Lutterman, J. A., & Smits, P. (1998) · Diabetologia · doi:10.1007/s001250050948 · Cited by 177
Boden, G., Homko, C., Mozzoli, M., Showe, L. C., Nichols, C., & Cheung, P. (2005) · Diabetes · doi:10.2337/diabetes.54.3.880 · Cited by 129
Akiyama, T. E., Lambert, G., Nicol, C. J., Matsusue, K., Peters, J. M., Brewer, H. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312802200 · Cited by 97
LDL particle size: an important drug target?
Rajman, I., Eacho, P. I., Chowienczyk, P. J., & Ritter, J. M. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00991.x · Cited by 51
Goya, K., Sumitani, S., Otsuki, M., Xu, X., Yamamoto, H., Kurebayashi, S., Saito, H., Kouhara, H., & Kasayama, S. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.08.003 · Cited by 43
McGuire, D. K., Abdullah, S. M., See, R., Snell, P. G., McGavock, J., Szczepaniak, L. S., Ayers, C. R., Drazner, M. H., Khera, A., & de Lemos, J. A. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq228 · Cited by 29
Metadata
- Authors
- Ghazzi, M. N., Perez, J. E., Antonucci, T. K., Driscoll, J. H., Huang, S. M., Faja, B. W., The Troglitazone Study Group, & Whitcomb, R. W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1997-03-01
- Volume
- 46
- Issue
- 3
- Pages
- 433-439
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1980198526
- Cited by
- 366
- References
- 0
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.